AR101801A1 - BENZAMIDE AND ACETAMIDE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE FOR THE PREPARATION OF A MEDICINAL PRODUCT - Google Patents
BENZAMIDE AND ACETAMIDE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE FOR THE PREPARATION OF A MEDICINAL PRODUCTInfo
- Publication number
- AR101801A1 AR101801A1 ARP150102883A ARP150102883A AR101801A1 AR 101801 A1 AR101801 A1 AR 101801A1 AR P150102883 A ARP150102883 A AR P150102883A AR P150102883 A ARP150102883 A AR P150102883A AR 101801 A1 AR101801 A1 AR 101801A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- functional
- pharmaceutically acceptable
- benzamide
- acid salt
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 Benzamide compound Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010010774 Constipation Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010012735 Diarrhoea Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 abstract 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 abstract 1
- 206010004593 Bile duct cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 201000001342 Fallopian tube cancer Diseases 0.000 abstract 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 abstract 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 abstract 1
- NJSDXTVEBPUEMH-UHFFFAOYSA-N N-[3-[2-(dimethylamino)ethoxy]-5-(trifluoromethyl)phenyl]-2-[4-(4-ethoxy-6-oxopiperidin-3-yl)-2-fluorophenyl]acetamide Chemical compound CCOC1CC(=O)NCC1c1ccc(CC(=O)Nc2cc(OCCN(C)C)cc(c2)C(F)(F)F)c(F)c1 NJSDXTVEBPUEMH-UHFFFAOYSA-N 0.000 abstract 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical class OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 208000014174 Oesophageal disease Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 abstract 1
- 206010036772 Proctalgia Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 208000028299 esophageal disease Diseases 0.000 abstract 1
- 210000003236 esophagogastric junction Anatomy 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 206010016766 flatulence Diseases 0.000 abstract 1
- 201000000117 functional diarrhea Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 208000037903 inflammatory enteropathy Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 238000010606 normalization Methods 0.000 abstract 1
- 201000002628 peritoneum cancer Diseases 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 abstract 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 abstract 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 abstract 1
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuesto de benzamida que es N-(2-(dimetilamino)etil)-3-(2-(4-(4-etoxi-6-oxo-1,6-dihidropiridin-3-il)-2-fluorofenil)acetamido)-5-(trifluorometil)benzamida, representado por la fórmula (1); o una sal farmacéuticamente aceptable del mismo. Compuesto de acetamida que es N-(3-(2-(dimetilamino)etoxi)-5-(trifluorometil)fenil)-2-(4-(4-etoxi-6-oxo-1,6-dihidropiridin-3-il)-2-fluorofenil)acetamida, representado por la fórmula (2) o una sal farmacéuticamente aceptable del mismo. Sales farmacéuticamente aceptables del compuesto benzamida que se seleccionan del grupo que consiste en la sal de ácido clorhídrico, la sal de ácido aspártico, la sal de ácido hipúrico y la sal de ácido fosfórico. Sus usos para la fabricación de medicamentos. Los compuestos son inhibidores de la cinasa RET (reorganizado durante la transfección) y se aplican para tratamientos, en monoterapia o en politerapia, para la normalización de la sensibilidad, movilidad y/o secreción gastrointestinal y/o trastornos o enfermedades abdominales y/o el tratamiento relacionado con enfermedades relacionadas con la disfunción de RET o en donde la modulación de la actividad de RET puede tener un beneficio terapéutico, que incluye, pero sin limitarse a ellos., todas las clasificaciones del síndrome del colon irritable (SCI), entre ellas el patrón de deposiciones donde predominan las diarreas, donde predomina el estreñimiento o su alternancia, meteorismo funcional, estreñimiento funcional, diarrea funcional, colon irritable funcional inespecífico, síndrome del dolor abdominal funcional, estreñimiento idiopático crónico., trastornos esofágicos funcionales, trastornos gastroduodenales funcionales, dolor anorrectal funcional, enteropatía inflamatoria, enfermedades proliferativas tales como cáncer de pulmón no microcítico, carcinoma hepatocelular, cáncer colorrectal, cáncer tiroideo medular, cáncer tiroideo folicular, cáncer tiroideo anaplásico, cáncer tiroideo papilar, tumores encefálicos, cáncer de la cavidad peritoneal, tumores sólidos, otro cáncer de pulmón, cáncer de cabeza y cuello, gliomas, neuroblastomas, síndrome de Von Hippel-Lindau y tumores de riñón, cáncer de mama, cáncer de las trompas de Falopio, cáncer de ovario, cáncer de las células de transición, cáncer de próstata, cáncer de esófago y de la unión gastroesofágica, cáncer biliar y adenocarcinoma, y cualquier neoplasia maligna con incremento de la actividad de la cinasa RET.Benzamide compound which is N- (2- (dimethylamino) ethyl) -3- (2- (4- (4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl) -2-fluorophenyl) acetamide) -5- (trifluoromethyl) benzamide, represented by formula (1); or a pharmaceutically acceptable salt thereof. Acetamide compound which is N- (3- (2- (dimethylamino) ethoxy) -5- (trifluoromethyl) phenyl) -2- (4- (4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl ) -2-fluorophenyl) acetamide, represented by formula (2) or a pharmaceutically acceptable salt thereof. Pharmaceutically acceptable salts of the benzamide compound that are selected from the group consisting of the hydrochloric acid salt, the aspartic acid salt, the hippuric acid salt and the phosphoric acid salt. Its uses for the manufacture of medicines. The compounds are inhibitors of RET kinase (reorganized during transfection) and are applied for treatments, in monotherapy or in polytherapy, for the normalization of gastrointestinal sensitivity, mobility and / or secretion and / or abdominal disorders or diseases and / or treatment related to diseases related to RET dysfunction or where modulation of RET activity can have a therapeutic benefit, which includes, but is not limited to., all classifications of irritable bowel syndrome (SCI), including the pattern of bowel movements where diarrhea predominates, where constipation or alternation predominates, functional meteorism, functional constipation, functional diarrhea, nonspecific functional irritable colon, functional abdominal pain syndrome, chronic idiopathic constipation., functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory enteropathy ria, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer , head and neck cancer, gliomas, neuroblastomas, von Hippel-Lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer esophagus and gastroesophageal junction, biliary cancer and adenocarcinoma, and any malignant neoplasm with increased activity of the RET kinase.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014086197 | 2014-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101801A1 true AR101801A1 (en) | 2017-01-11 |
Family
ID=58698679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102883A AR101801A1 (en) | 2014-09-10 | 2015-09-10 | BENZAMIDE AND ACETAMIDE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR101801A1 (en) |
-
2015
- 2015-09-10 AR ARP150102883A patent/AR101801A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095308A1 (en) | COMPOSITE OF 2-PIRIDONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT | |
| EA201591738A1 (en) | PYRIDINE DERIVATIVES AS AN INHIBITORS OF REINREGED TRANSFECTION (RET) KINASE | |
| DOP2017000059A (en) | NEW COMPOUNDS AS RET INHIBITORS (REORGANIZED DURING TRANSFECTION) | |
| DOP2017000067A (en) | NEW COMPOUNDS AS REORGANIZED INHIBITORS DURING TRANSFECTION (RET) | |
| PH12019500231A1 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| RU2015121424A (en) | COMBINED THERAPY | |
| RU2018138828A (en) | TUMOR MASS REDUCTION BY INTRODUCING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | |
| MX393318B (en) | BICYCLIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT | |
| HRP20190805T1 (en) | Triazolopyrimidine compounds and uses thereof | |
| RU2018102963A (en) | ANILINPYRIMIDINE DERIVATIVES AND THEIR APPLICATIONS | |
| EA202092054A1 (en) | PIPERIDINYL-3- (ARYLOXY) PROPANAMIDES AND PROPANOATES | |
| JP2016053042A5 (en) | ||
| HRP20220886T1 (en) | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity | |
| RU2017122062A (en) | COMPOUND 2-AMINOPYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND APPLICATION OF THIS COMPOUND | |
| PE20151601A1 (en) | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USE | |
| HRP20191826T4 (en) | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway | |
| DOP2011000325A (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A LIQUID SOLUTION THAT INCLUDES N- (4- (4 - ((2- (4-CHLOROPHENYL) -5,5-DIMETHYL-1-CICLOHEX-1-EN-1-IL) METHYL) PIPERAZIN- 1-IL) BENZOIL) -4- (((1R) -3- (MORFOLIN-4-IL) -1 - ((FENILSULFANIL) METHYL) PROPIL) AMINO-3 - ((TRIFLUOROMETIL) SULFONIL) BENCENOSULFONAMIDE (ABT-263 ) | |
| AR100818A1 (en) | N- (CYANOMETIL) -4- (2- (4-MORFOLINOFENILAMINO) PIRIMIDIN-4-IL) BENZAMIDA | |
| RU2014119339A (en) | UREA 2-CARBOXAMIDE CYCLOAMINO DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATMENT OF PROLIFERATIVE DISEASES | |
| PE20181017A1 (en) | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | |
| AR119614A1 (en) | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUOR-1,2,3,4-TETRAHYDRONAPTHALENE-2-IL)AMINO)-N-(1-(2-METHYL- 1-(NEOPENTYLAMINO)PROPAN-2-IL)-1H-IMIDAZOL-4-IL)PENTANAMIDE AND USES THEREOF | |
| RU2013143520A (en) | NEW CHEMICAL COMPOUNDS (OPTIONS) AND THEIR APPLICATION FOR TREATMENT OF ONCOLOGICAL DISEASES | |
| ES2537529T3 (en) | Novel modulators of protein kinase signaling | |
| RU2018122012A (en) | BIS-pyridazine compounds and their use in the treatment of cancer | |
| AR101801A1 (en) | BENZAMIDE AND ACETAMIDE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |